利用[44Sc]Sc-PSMA-617药代动力学预测转移性去势抵抗性前列腺癌患者[177Lu]Lu-PSMA-617的正常器官吸收剂量
在5例转移性去势抵抗性前列腺癌患者中,用[44Sc]Sc-PSMA-617行动态及静态PET/CT和血尿采样,经衰变校正外推至[177Lu]Lu-PSMA-617,用OLINDA/EXM计算正常器官吸收剂量与最大允许活度。预测平均吸收剂量以肾脏最高(0.44 mSv/MBq),其次为唾液腺(0.23 mSv/MBq);最大允许活度受全身、骨髓或肾脏剂量限制而个体差异大。作者认为[44Sc]Sc-PSMA-617 PET/CT可行,可用于理论外推预测正常器官剂量和最大允许活度。
要点
- 5例患者中预测平均器官吸收剂量肾脏最高(0.44 mSv/MBq),唾液腺次之(0.23 mSv/MBq)。
- 最大允许活度个体间差异大,分别受全身(1例)、骨髓(1例)和肾脏(3例)吸收剂量限制。
- [44Sc]Sc-PSMA-617 PET/CT可行,可理论外推至[177Lu]Lu-PSMA-617药代动力学。
核心结论
- [44Sc]Sc-PSMA-617 PET/CT显像可行,可将[44Sc]Sc-PSMA-617药代动力学理论外推至[177Lu]Lu-PSMA-617,以预测计划治疗患者的正常器官吸收剂量和最大允许活度。
研究设计与样本
- 在5例转移性去势抵抗性前列腺癌患者中评估[44Sc]Sc-PSMA-617药代动力学,行动态PET/CT后行3次静态PET/CT采集,并在19.5小时内采集血样,于2个时间点采集尿样。
- 将PET测得的源器官总活度及血、尿样本每毫升计数按Sc半衰期衰变校正回注射时间,再按Lu半衰期行正向衰变校正,将[44Sc]Sc-PSMA-617药代动力学外推至[177Lu]Lu-PSMA-617。
- 用OLINDA/EXM软件计算[177Lu]Lu-PSMA-617源器官滞留时间和器官吸收剂量;骨髓自身剂量用基于血液的间接法确定,膀胱内容物滞留时间用梯形近似估算。
- 按外照射放疗对肾脏、骨髓、唾液腺和全身辐射吸收剂量的毒性限值,计算每例患者[177Lu]Lu-PSMA-617的最大允许活度。
主要发现
- 预测平均器官吸收剂量以肾脏最高(0.44 mSv/MBq),其次为唾液腺(0.23 mSv/MBq)。
- 最大允许活度在患者间差异很大,分别受全身吸收剂量(1例)、骨髓吸收剂量(1例)和肾脏吸收剂量(3例)限制。
关键数值与推荐
- 预测平均肾脏吸收剂量为0.44 mSv/MBq,预测平均唾液腺吸收剂量为0.23 mSv/MBq。
- 最大允许活度按外照射放疗对肾脏、骨髓、唾液腺和全身辐射吸收剂量的毒性限值计算,患者间差异大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. METHODS: Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in blood and urine samples, was decay corrected back to the time of injection using the half-life of Sc. Afterward, forward decay correction using the half-life of Lu was performed, extrapolating the pharmacokinetics of [Sc]Sc-PSMA-617 to that of [Lu]Lu-PSMA-617. Source organs residence times and organ-absorbed doses for [Lu]Lu-PSMA-617 were calculated using OLINDA/EXM software. Bone marrow self-dose was determined with indirect blood-based method, and urinary bladder contents residence time was estimated by trapezoidal approximation. The maximum permissible activity of [Lu]Lu-PSMA-617 was calculated for each patient considering external beam radiotherapy toxicity limits for radiation absorbed doses to kidneys, bone marrow, salivary glands, and whole body. RESULTS: The predicted mean organ-absorbed doses were highest in the kidneys (0.44 mSv/MBq), followed by the salivary glands (0.23 mSv/MBq). The maximum permissible activity was highly variable among patients; limited by whole body-absorbed dose (1 patient), marrow-absorbed dose (1 patient), and kidney-absorbed dose (3 patients). CONCLUSIONS: [Sc]Sc-PSMA-617 PET/CT imaging is feasible and allows theoretical extrapolation of the pharmacokinetics of [Sc]Sc-PSMA-617 to that of [Lu]Lu-PSMA-617, with the intent of predicting normal organ-absorbed doses and maximum permissible activity in patients scheduled for therapy with [Lu]Lu-PSMA-617.
引用
- Khawar A, Eppard E, Sinnes JP, et al. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma. Clin Nucl Med. 2018. PMID: 29688951. doi:10.1097/RLU.0000000000002102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。